Research programme: cardio-protective therapeutics - CapellaBio/Stem cell Theranostics

Drug Profile

Research programme: cardio-protective therapeutics - CapellaBio/Stem cell Theranostics

Alternative Names: chemoprotectants - CapellaBio/Stem Cell Theranostics

Latest Information Update: 11 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CapellaBio; Stem Cell Theranostics
  • Class Cardiotonics
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Acute heart failure

Most Recent Events

  • 16 Dec 2015 Stem Cell Theranostics and CapellaBio agree to co-develop therapeutics in USA for Acute heart failure (Prevention)
  • 16 Dec 2015 Early research in Acute heart failure (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top